Methoxy polyethylene glycol-epoetin beta in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins
METOXI-POLIETILENGLICOL EPOETINA BETA (MIRCERA®) EN EL TRATAMIENTO DE UNA PACIENTE CON ENFERMEDAD RENAL CRÓNICA Y QUE PRESENTA HIPERSENSIBILIDAD RETARDADA A OTRAS EPOETINAS
Read
8629
Timeswas read the article
2381
Total PDF
6248
Total HTML
Share statistics
array:21 [ "pii" => "X2013251410035709" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Mar.10310" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:372-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4248 "formatos" => array:3 [ "EPUB" => 314 "HTML" => 3350 "PDF" => 584 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699510035701" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2010.Mar.10310" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2010;30:372-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 16203 "formatos" => array:3 [ "EPUB" => 329 "HTML" => 15143 "PDF" => 731 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "METOXI-POLIETILENGLICOL EPOETINA BETA (MIRCERA®) EN EL TRATAMIENTO DE UNA PACIENTE CON ENFERMEDAD RENAL CRÓNICA Y QUE PRESENTA HIPERSENSIBILIDAD RETARDADA A OTRAS EPOETINAS" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "372" "paginaFinal" => "373" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Methoxy polyethylene glycol-epoetin beta in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Cristina Lucía Dávila Fajardo, María Peña Ortega, José Cabeza Barrera, Mª Dolores Prados Garrido" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Cristina Lucía" "apellidos" => "Dávila Fajardo" ] 1 => array:2 [ "nombre" => "María" "apellidos" => "Peña Ortega" ] 2 => array:2 [ "nombre" => "José" "apellidos" => "Cabeza Barrera" ] 3 => array:2 [ "nombre" => "Mª Dolores" "apellidos" => "Prados Garrido" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251410035709" "doi" => "10.3265/Nefrologia.pre2010.Mar.10310" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035709?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035701?idApp=UINPBA000064" "url" => "/02116995/0000003000000003/v0_201502091325/X0211699510035701/v0_201502091326/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251410035717" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Mar.10271" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:373-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5069 "formatos" => array:3 [ "EPUB" => 275 "HTML" => 4308 "PDF" => 486 ] ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Decrease in renal function due to myomatous uterus" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "373" "paginaFinal" => "374" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Deterioro de función renal por útero miomatoso" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "10271_18030_5948_en_figure1.jpg" "Alto" => 488 "Ancho" => 657 "Tamanyo" => 158221 ] ] "descripcion" => array:1 [ "en" => "CT cut where bilateral hydronephrosis can be seen." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alejandra Rodriguez, Rita Guerra, Diego Silva" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Alejandra" "apellidos" => "Rodriguez" ] 1 => array:2 [ "nombre" => "Rita" "apellidos" => "Guerra" ] 2 => array:2 [ "nombre" => "Diego" "apellidos" => "Silva" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X021169951003571X" "doi" => "10.3265/Nefrologia.pre2010.Mar.10271" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169951003571X?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035717?idApp=UINPBA000064" "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035717/v0_201502091604/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X201325141003575X" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2010.Mar.10258" "estado" => "S300" "fechaPublicacion" => "2010-05-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2010;30:371-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4596 "formatos" => array:3 [ "EPUB" => 289 "HTML" => 3738 "PDF" => 569 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Treatment with intravenous iron and ferritin level" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "371" "paginaFinal" => "372" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "TRATAMIENTO CON HIERRO INTRAVENOSO Y NIVEL DE FERRITINA" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Fernández-Gallego, María Adoración Martín, Seema Sujan, Encarnacion Vega" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Juan" "apellidos" => "Fernández-Gallego" ] 1 => array:2 [ "nombre" => "María Adoración" "apellidos" => "Martín" ] 2 => array:2 [ "nombre" => "Seema" "apellidos" => "Sujan" ] 3 => array:2 [ "nombre" => "Encarnacion" "apellidos" => "Vega" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699510035752" "doi" => "10.3265/Nefrologia.pre2010.Mar.10258" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699510035752?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141003575X?idApp=UINPBA000064" "url" => "/20132514/0000003000000003/v0_201502091603/X201325141003575X/v0_201502091604/en/main.assets" ] "en" => array:11 [ "idiomaDefecto" => true "titulo" => "Methoxy polyethylene glycol-epoetin beta in the treatment of a patient with chronic kidney disease presenting late-onset hypersensitivity to other epoetins" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "372" "paginaFinal" => "373" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Cristina Lucía Dávila Fajardo, María Peña Ortega, José Cabeza Barrera, Mª Dolores Prados Garrido" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Cristina Lucía" "apellidos" => "Dávila Fajardo" "email" => array:1 [ 0 => "cldf28@hotmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "María" "apellidos" => "Peña Ortega" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "José" "apellidos" => "Cabeza Barrera" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] 3 => array:3 [ "nombre" => "Mª Dolores" "apellidos" => "Prados Garrido" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Farmacia, Hospital Universitario San Cecilio de Granada, Granada, Granada, España, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Nefrología, Hospital Universitario San Cecilio de Granada, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] 2 => array:3 [ "entidad" => "Farmacia, Hospital Universitario San Cecilio de Granada, " "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "affc" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "METOXI-POLIETILENGLICOL EPOETINA BETA (MIRCERA®) EN EL TRATAMIENTO DE UNA PACIENTE CON ENFERMEDAD RENAL CRÓNICA Y QUE PRESENTA HIPERSENSIBILIDAD RETARDADA A OTRAS EPOETINAS" ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Dear Editor, </span> </p><p class="elsevierStylePara"> Methoxy polyethylene glycol-epoetin beta (Mircera<span class="elsevierStyleSup">®</span>) is a recombinant erythropoietin that, just like natural erythropoietin, stimulates red blood cell production and increases blood levels of haemoglobin, by interacting with the erythropoietin receptors on marrow progenitor cells, thus resulting in continuous activation.<span class="elsevierStyleSup">1-3 </span> </p><p class="elsevierStylePara"> We present the case of a patient with Stage 5 chronic kidney disease (CKD) who had a delayed hypersensitivity reaction on two recombinant erythropoietins. In August 2004, treatment was started with epoetin beta (Neorrecormon<span class="elsevierStyleSup">©</span>) subcutaneously. Six months later the patient developed pruritus and generalised micropapular lesions in direct relation to the weekly administration of this anti-anaemic medication.  </p><p class="elsevierStylePara"> The patient was then treated with darbepoetin alpha (Aranesp<span class="elsevierStyleSup">®</span>) subcutaneously, and, starting with the first dose, developed a similar skin reaction to that described with epoetin beta, for which the medication was suspended. In April 2006, the patient started haemodialysis, and intravenous administration of darbepoetin alpha was started and was well tolerated over several administrations. However, on two occasions, the patient developed palmoplantar pruritus and papular lesions that required withdrawal of the drug. Subsequently, the patient needed monthly red cell transfusions, due to persistent anaemia secondary to CKD. In September 2007, authorisation was requested from the Spanish Ministry of Health and Consumer Affairs for the foreign medication epoetin delta, but authorisation was refused on the grounds that there was a high probability of having a reaction to it given the patient’s history. Faced with this situation, in August 2009 we decided to try pegylated epoetin beta (Mircera<span class="elsevierStyleSup">®</span>), which has been registered in Spain since July 2007,<span class="elsevierStyleSup">1 </span>while monitoring for tolerance and effectiveness.  </p><p class="elsevierStylePara"> Based on recommendations from the Allergy department, escalating doses (12.5, 25 and 37.5μg) of pegylated epoetin beta were administered subcutaneously at seven day intervals until reaching the final dose of 50μg (0.6μg/kg), without any adverse reaction. We continued to administer pegylated epoetin beta at the 50μg dose, but divided into two injections (25μg) for the first three doses.  </p><p class="elsevierStylePara"> At present, and after eight fortnightly intravenous doses of pegylated epoetin beta, we can state that the patient is tolerating this treatment, maintaining sustained haemoglobin and haematocrit levels within the recommended range for stage 5 CKD on haemodialysis. In this instance, the intravenous administration of pegylated epoetin beta did not result in the appearance of any crossreactions arising from the patient’s intolerance to epoetin beta and darbepoetin alpha. Therefore, we suggest that pegylated epoetin beta may be a good alternative for treating chronic anaemia in patients with CKD and intolerance to epoetin beta and darbepoetin alpha. <span class="elsevierStyleBold"> </span></p>" "pdfFichero" => "P1-E46-S1860-A10310-EN.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:2 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec437236" "palabras" => array:1 [ 0 => "Anemia" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec437238" "palabras" => array:1 [ 0 => "Kidney disease" ] ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "BIBLIOGRAFÍA" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "1-\u{A0}\u{A0}\u{A0} Ficha técnica metoxi-polietilenglicol epoetina ¿ (Mircera®) http://www.ema.europa.eu/humandocs/PDFs/EPAR/mircera/H-739-PI-es.pdf." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "2-\u{A0}\u{A0}\u{A0} Committee for Medicinal Products for Human Use, European Medicines Agency. Scientific discussion. En: Mircera: European public assessment report. London: EMEA; 2007. http://www.emea.europa.eu/humandocs/PDFs/EPAR/mircera/H-739-en6.pdf" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "3-\u{A0}\u{A0}\u{A0} Center for Drug Evaluation and Research. Mircera® (methoxy polyethylene glycol-epoetin beta) [Drug Product Label] U.S. Food and Drug Administration; 2007 Nov 14. FDA Application no (NDA) 125164. Disponible en: http://www.fda.gov/cder/foi/label/2007/125164lbl.pdf" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003000000003/v0_201502091603/X2013251410035709/v0_201502091604/en/main.assets" "Apartado" => array:4 [ "identificador" => "35436" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003000000003/v0_201502091603/X2013251410035709/v0_201502091604/en/P1-E46-S1860-A10310-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251410035709?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 14 | 9 | 23 |
| 2024 October | 68 | 43 | 111 |
| 2024 September | 88 | 29 | 117 |
| 2024 August | 87 | 65 | 152 |
| 2024 July | 57 | 24 | 81 |
| 2024 June | 68 | 36 | 104 |
| 2024 May | 64 | 36 | 100 |
| 2024 April | 69 | 36 | 105 |
| 2024 March | 47 | 27 | 74 |
| 2024 February | 34 | 27 | 61 |
| 2024 January | 44 | 20 | 64 |
| 2023 December | 32 | 21 | 53 |
| 2023 November | 56 | 33 | 89 |
| 2023 October | 42 | 31 | 73 |
| 2023 September | 43 | 33 | 76 |
| 2023 August | 41 | 19 | 60 |
| 2023 July | 62 | 28 | 90 |
| 2023 June | 50 | 30 | 80 |
| 2023 May | 58 | 42 | 100 |
| 2023 April | 33 | 26 | 59 |
| 2023 March | 45 | 29 | 74 |
| 2023 February | 34 | 21 | 55 |
| 2023 January | 39 | 28 | 67 |
| 2022 December | 49 | 29 | 78 |
| 2022 November | 52 | 53 | 105 |
| 2022 October | 47 | 44 | 91 |
| 2022 September | 48 | 43 | 91 |
| 2022 August | 49 | 58 | 107 |
| 2022 July | 39 | 39 | 78 |
| 2022 June | 43 | 45 | 88 |
| 2022 May | 51 | 37 | 88 |
| 2022 April | 37 | 51 | 88 |
| 2022 March | 53 | 61 | 114 |
| 2022 February | 39 | 39 | 78 |
| 2022 January | 42 | 34 | 76 |
| 2021 December | 39 | 48 | 87 |
| 2021 November | 36 | 33 | 69 |
| 2021 October | 48 | 62 | 110 |
| 2021 September | 35 | 41 | 76 |
| 2021 August | 46 | 41 | 87 |
| 2021 July | 44 | 38 | 82 |
| 2021 June | 30 | 34 | 64 |
| 2021 May | 60 | 34 | 94 |
| 2021 April | 139 | 42 | 181 |
| 2021 March | 77 | 22 | 99 |
| 2021 February | 71 | 24 | 95 |
| 2021 January | 43 | 13 | 56 |
| 2020 December | 35 | 13 | 48 |
| 2020 November | 43 | 10 | 53 |
| 2020 October | 22 | 9 | 31 |
| 2020 September | 24 | 16 | 40 |
| 2020 August | 47 | 10 | 57 |
| 2020 July | 53 | 14 | 67 |
| 2020 June | 52 | 9 | 61 |
| 2020 May | 71 | 16 | 87 |
| 2020 April | 52 | 15 | 67 |
| 2020 March | 81 | 21 | 102 |
| 2020 February | 46 | 16 | 62 |
| 2020 January | 52 | 22 | 74 |
| 2019 December | 76 | 26 | 102 |
| 2019 November | 66 | 20 | 86 |
| 2019 October | 36 | 7 | 43 |
| 2019 September | 59 | 24 | 83 |
| 2019 August | 25 | 13 | 38 |
| 2019 July | 37 | 22 | 59 |
| 2019 June | 51 | 17 | 68 |
| 2019 May | 36 | 22 | 58 |
| 2019 April | 59 | 31 | 90 |
| 2019 March | 35 | 22 | 57 |
| 2019 February | 29 | 16 | 45 |
| 2019 January | 16 | 15 | 31 |
| 2018 December | 52 | 33 | 85 |
| 2018 November | 59 | 10 | 69 |
| 2018 October | 51 | 14 | 65 |
| 2018 September | 61 | 21 | 82 |
| 2018 August | 47 | 18 | 65 |
| 2018 July | 47 | 14 | 61 |
| 2018 June | 44 | 8 | 52 |
| 2018 May | 49 | 17 | 66 |
| 2018 April | 60 | 10 | 70 |
| 2018 March | 60 | 15 | 75 |
| 2018 February | 44 | 7 | 51 |
| 2018 January | 42 | 10 | 52 |
| 2017 December | 48 | 6 | 54 |
| 2017 November | 33 | 8 | 41 |
| 2017 October | 26 | 5 | 31 |
| 2017 September | 26 | 12 | 38 |
| 2017 August | 24 | 9 | 33 |
| 2017 July | 35 | 15 | 50 |
| 2017 June | 34 | 13 | 47 |
| 2017 May | 41 | 16 | 57 |
| 2017 April | 41 | 9 | 50 |
| 2017 March | 26 | 1 | 27 |
| 2017 February | 26 | 5 | 31 |
| 2017 January | 28 | 10 | 38 |
| 2016 December | 38 | 4 | 42 |
| 2016 November | 55 | 8 | 63 |
| 2016 October | 95 | 5 | 100 |
| 2016 September | 94 | 4 | 98 |
| 2016 August | 122 | 5 | 127 |
| 2016 July | 109 | 5 | 114 |
| 2016 June | 115 | 0 | 115 |
| 2016 May | 152 | 0 | 152 |
| 2016 April | 84 | 0 | 84 |
| 2016 March | 90 | 0 | 90 |
| 2016 February | 110 | 0 | 110 |
| 2016 January | 110 | 0 | 110 |
| 2015 December | 123 | 0 | 123 |
| 2015 November | 92 | 0 | 92 |
| 2015 October | 76 | 0 | 76 |
| 2015 September | 74 | 0 | 74 |
| 2015 August | 67 | 0 | 67 |
| 2015 July | 52 | 0 | 52 |
| 2015 June | 31 | 0 | 31 |
| 2015 May | 54 | 0 | 54 |
| 2015 April | 6 | 0 | 6 |
Show all
